There’s more to the company’s leading product than meets the eye.
It’s one thing for a pharmaceutical company to have a blockbuster drug in its portfolio. It’s quite another if such a product can be successfully extended to win approvals for other indications.
This is one huge reason to believe in the future of Novo Nordisk (NVO 1.82%), the Danish company behind the immensely popular Wegovy obesity treatment. Last week the company earned a new feather in its cap with the product, and it feels as if it has far more distance to go with drug discovery.
Wegovy has legs
In mid-August the company hit paydirt when the U.S. Food and Drug Administration (FDA) approved it as a treatment for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adult patients with moderate to advanced liver fibrosis. The drug is intended to be used in combination with an increase in physical activity, and a reduction in caloric food intake.
Image source: Getty Images.
It probably goes without saying that America’s obesity problem affects far more individuals than does MASH.
But Novo Nordisk’s successful development of the drug to treat the liver disorder demonstrates two very positive things; 1) Wegovy (and by extension its sibling medication, Ozempic) has the potential to treat numerous other afflictions and, 2) generally, the company is adept at developing its molecules for a variety of indications.
Pipeline to greater success?
Novo Nordisk has quite the impressively wide pipeline, and semaglutide (the molecule which is the primary ingredient of Wegovy and Ozempic) is only one part of it. It’s in the later stages of investigating the drug for treatment of Alzheimer’s; meanwhile, it’s got a host of other molecules in programs aimed in many therapeutic directions.
With such a high pitch of activity, the future is bright for semaglutide and other investigational drugs. And, by extension, their developer.
Great Job newsfeedback@fool.com (Eric Volkman) & the Team @ The Motley Fool Source link for sharing this story.
